Khetan, R.; Lokman, N.A.; Eldi, P.; Price, Z.K.; Oehler, M.K.; Brooks, D.A.; Blencowe, A.; Garg, S.; Ricciardelli, C.; Albrecht, H.
Protease-Activated Receptor F2R Is a Potential Target for New Diagnostic/Prognostic and Treatment Applications for Patients with Ovarian Cancer. Int. J. Mol. Sci. 2025, 26, 8529.
https://doi.org/10.3390/ijms26178529
AMA Style
Khetan R, Lokman NA, Eldi P, Price ZK, Oehler MK, Brooks DA, Blencowe A, Garg S, Ricciardelli C, Albrecht H.
Protease-Activated Receptor F2R Is a Potential Target for New Diagnostic/Prognostic and Treatment Applications for Patients with Ovarian Cancer. International Journal of Molecular Sciences. 2025; 26(17):8529.
https://doi.org/10.3390/ijms26178529
Chicago/Turabian Style
Khetan, Riya, Noor A. Lokman, Preethi Eldi, Zoe K. Price, Martin K. Oehler, Doug A. Brooks, Anton Blencowe, Sanjay Garg, Carmela Ricciardelli, and Hugo Albrecht.
2025. "Protease-Activated Receptor F2R Is a Potential Target for New Diagnostic/Prognostic and Treatment Applications for Patients with Ovarian Cancer" International Journal of Molecular Sciences 26, no. 17: 8529.
https://doi.org/10.3390/ijms26178529
APA Style
Khetan, R., Lokman, N. A., Eldi, P., Price, Z. K., Oehler, M. K., Brooks, D. A., Blencowe, A., Garg, S., Ricciardelli, C., & Albrecht, H.
(2025). Protease-Activated Receptor F2R Is a Potential Target for New Diagnostic/Prognostic and Treatment Applications for Patients with Ovarian Cancer. International Journal of Molecular Sciences, 26(17), 8529.
https://doi.org/10.3390/ijms26178529